title: Possible role of hepatocyte growth factor in regeneration of human peritoneal mesothelial cells.
abstract: Human peritoneal mesothelial cells (HPMCs) play an important role in peritoneal functions. During long term peritoneal dialysis, it has been reported that HPMCs are damaged by high glucose solution via the signal of transforming growth factor (TGF)-beta1 produced by HPMCs. In this study, we focused on the effect of hepatocyte growth factor (HGF), known as an anti-fibrotic and anti-TGF-beta1 agent, on HPMCs damaged by high glucose solution. HPMCs were isolated from specimens of the omentum from nonuremic patients after informed consent had been obtained. After confirming adhesion for 6 hours, 100 microL of DMEM with 0.5%FCS were added at different concentrations (D-glucose; 6, 30 mM) with or without HGF (10, 30, 100 ng/mL) for 48 hours. We examined the effects of a high concentration of glucose and then focused on following four critical points: 1) the production of HGF from HPMCs exposed to a high concentration of glucose, 2) the expression of c-Met on HPMCs, 3) the viability of those cells, and 4) matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinase-2 (TIMP-2). The following significant changes are described herein: high glucose solution and TGF-beta1 i) decreased HGF production from HPMCs and ii) up-regulated expression of c-Met on HPMCs, and addition of HGF iii) restored viability of HPMCs damaged by glucose, iv) suppressed TGF-beta1 production by HGF, and v) induced up-regulation of MMP-2 and decreased TIMP-2 production by HPMCs. Levels of HGF decreased by high concentrations of glucose in the peritoneal cavity may induce the loss of HPMCs and thereby result in peritoneal fibrosis. These results suggest that HGF is an effective agent in the regeneration of peritoneal membrane damaged by high glucose solution.
authors.affiliation: Department of Internal Medicine, Division of Hematology, Nephrology and Rheumatology, Kinki University School of Medicine, 377-2, Ohno-Hogashi, Osaka-Sayama, Osaka 589 8511, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Naiki
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: T
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
mesh_terms: D049109:Cell Proliferation; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000502:physiology*; D005434:Flow Cytometry; D005950:Glucose Solution, Hypertonic; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000187:drug effects; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000166:cytology*; D019859:Proto-Oncogene Proteins c-met / Q000187:drug effects; D012038:Regeneration; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D053773:Transforming Growth Factor beta1
chemical_list: D005950:Glucose Solution, Hypertonic; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D019716:Tissue Inhibitor of Metalloproteinase-2; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met; D020778:Matrix Metalloproteinase 2